Dolomite and Clearbridge develop revolutionary instrument for cancer detection
Microfluidics expert, Dolomite, is delighted to announce its collaboration with Clearbridge BioMedics in the development of a novel instrument capable of detecting and isolating Circulating Tumour Cells (CTCs) from small quantities of whole, unprocessed blood.
|
|
|
The innovative ClearCell™ System can isolate, enumerate and most importantly retrieve wholly intact and viable CTCs from patient whole blood. Benefiting a broad range of application areas including molecule analysis, cancer diagnostics and cancer treatment decisions, this revolutionary instrument also paves the way for personalised cancer medication for patients.
|
Speaking of this success, Andrew Lovatt, the CEO of Dolomite, says, “We are excited to be working with an innovative company like Clearbridge BioMedics. The collaboration is an excellent example of how Dolomite is able to help start-up companies productize science. By combining the cutting edge scientific research of Clearbridge BioMedics and National University of Singapore with the proven track record in product development of Dolomite, both companies have leveraged their expertise to gain early traction in the novel field of automated capture of viable CTCs. We are looking forward to extending our partnership beyond research tools and into the clinical diagnostic domain."
|
|
|
“We see microfluidics playing an increasing key role in many Companion Diagnostics and In-Vitro Diagnostics devices. Dolomite has demonstrated that they are indeed a leader in this field, and we look forward to developing our future platform devices and systems together“, commented Johnson Chen, Managing Director of Clearbridge BioMedics.
|
About Clearbridge BioMedics
Clearbridge BioMedics is a spin-off from the National University of Singapore (NUS), and an incubatee of Clearbridge Accelerator, a Singapore Government backed high-technology incubator. Leveraging on a microfluidic biochip invention, its ClearCell™ System comprises patent-pending microfluidic CTChips®, which are able to effectively detect and isolate wholly-intact CTCs (Circulating Tumour Cells) from small quantities of whole patient blood samples.
Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America.
For more information on Clearbridge BioMedics’ ClearCell™ System and CTChip®, please visit www.ClearbridgeBioMedics.com
More press releases >>
|
corporate 